IN THE SPOTLIGHT

Frontline Alecensa Extends Survival in Advanced ALK-Positive Lung Cancer

Frontline Alecensa Extends Survival in Advanced ALK-Positive Lung Cancer

Frontline Alecensa Extends Survival in Advanced ALK-Positive Lung Cancer

Frontline Alecensa Extends Survival in Advanced ALK-Positive Lung Cancer

Genprex’s gene therapy shows promise for ALK-positive lung cancer By Investing.com

Genprex’s gene therapy shows promise for ALK-positive lung cancer By Investing.com

Cancer-Related Cause of Death and End-of-Life Management in Patients With ALK-Rearranged NSCLC

Cancer-Related Cause of Death and End-of-Life Management in Patients With ALK-Rearranged NSCLC

-Chugai Pharmaceutical - Alecensa Extends Median Overall Survival to Over 80 Months in ALK-Positive Metastatic Non-Small Cell Lung Cancer

-Chugai Pharmaceutical - Alecensa Extends Median Overall Survival to Over 80 Months in ALK-Positive Metastatic Non-Small Cell Lung Cancer

Chugai Pharmaceutical: Alecensa Extends Median Overall Survival to Over 80 Months in ALK-Positive Metastatic Non-Small Cell Lung Cancer

Chugai Pharmaceutical: Alecensa Extends Median Overall Survival to Over 80 Months in ALK-Positive Metastatic Non-Small Cell Lung Cancer

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer

Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer

Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung cancer

Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung cancer

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.